Highlights Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-20 EDT			5-day change	1st Jan Change
1.4 ^USD	-2.10%		+6.06%	-28.93%

05-13	Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-12	Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
North American Morning Briefing : Inflation Data -2-	03-12	DJ
Ikena Oncology, Inc. Provides Corporate Updates	01-18	CI
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial	11-09	CI
Ikena Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Ikena Oncology Shares Fall After Pionyr Immunotherapeutics Acquisition Completed	23-08-07	MT
Ikena Oncology Completes Acquisition of Pionyr Immunotherapeutics in All-Stock Deal	23-08-07	MT
Ikena Oncology, Inc. acquired Pionyr Immunotherapeutics Inc..	23-08-03	CI
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Ikena Oncology, Inc. Announces Preclinical Data in the Novel Investigational Hippo Pathway Inhibitor, Ik-930	23-04-17	CI
IKENA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-14	AQ
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Ikena Oncology Presents Preclinical Data on Ik-595, Best-In-Class Next-Generation Mek-Raf Complex Inhibitor, in Plenary Session At Aacr Special Conference on Ras Targeting	23-03-07	CI
Ikena Oncology Gets FDA Fast Track Label for IK-175 Plus Nivolumab to Treat Urothelial Carcinoma	23-03-06	MT
Ikena Oncology, Inc. Receives FDA Fast Track Designation for Novel Ahr Antagonist Ik-175 in Combination with Nivolumab to Treat Urothelial Carcinoma	23-03-06	CI
Ikena Oncology, Inc. Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update	22-11-28	CI
Ikena Oncology, Inc. Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Highlights

Filters